CAPRISA 018
Status:Ongoing
Phase:I
Principal Investigator(s):
Objective:The proposed CAPRISA 018 trial aims to primarily assess the safety, acceptability and pharmacokinetics (PK) of the TAF implant, and secondarily to obtain a preliminary estimate of efficacy for HIV prevention in young South African women
Prevention Option(s):PrEP
Study Design:
Arms and Assigned Interventions
DescriptionTenofovir Alafenamide (TAF) Implant
Mode of Delivery
ARMs
Official Code:
CAPRISA 018
Trial Sponsors:
Centre for the AIDS Programme of Research in South Africa, Saint-Etienne, Stichting Amsterdam Institute for Global Health and Development, Université Jean Monnet
Start Date
End Date
January 1, 2017
December 31, 2022
Enrollment:0
Age range:
↔
any
Population:Cisgender Women